MCM7 Antibodies

DNA replication licensing factor MCM7 (MCM7)

Acts as component of this MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. The active ATPase sites in the MCM2-7 ring have been formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding website of the Walker A box of the adjacent subunit.

The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Required for S-phase checkpoint activation upon UV-induced damage.

Gene Information

Human
Gene Name:	MCM7
Uniprot:	P33993
Entrez:	4176

Family

Belongs to:
MCM family

Alternative Names

CDC47 homolog; CDC47; CDC47P85MCM; DNA replication licensing factor MCM7; EC 3.6.4.12; homolog of S. cerevisiae Cdc47; MCM2; MCM2PNAS146; MCM7 minichromosome maintenance deficient 7 (S. cerevisiae); MCM7; minichromosome maintenance complex component 7; minichromosome maintenance deficient (S. cerevisiae) 7; minichromosome maintenance deficient 7; P1.1-MCM3; P1CDC47; P85MCM; PNAS146; PPP1R104; Protein Phosphatase 1

Molecular Weight

Mass (kDA):
81.308 kDA

Genomic Context

Human
Location:	7q22.1
Sequence:	7; NC_000007.14 (100092728..100101397, complement)

Subcellular Localizations

Nucleus.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Malignant Paraganglionic Neoplasm
• Retinoblastoma
• Prostatic Neoplasms
• Adenocarcinoma
• Malignant Neoplasm Of Prostate
• Cell Transformation, Neoplastic
• Dysplasia
• Malignant Tumor Of Cervix
• Malignant Squamous Cell Neoplasm
• Hyperplasia

• Neoplasm Metastasis
• Cell Invasion
• Uterine Cervical Neoplasm
• Malignant Neoplasm Of Breast
• Carcinogenesis
• Mammary Neoplasms
• Skin Neoplasms

Interacting Proteins

• AK8
• CCDC102B
• CDC6
• CDKN1B
• CDKN1C

• GOLGA2
• INTS6
• KIFC3
• LYN
• MCM2

• MCM4
• MCM5
• MCM6
• MCMBP
• MIPOL1

• MYC
• NAB2
• PLK1
• PNMA1
• SMC1A

• SP2
• SSRP1
• TRIM27
• TRIM54
• UBB

• USHBP1

Pathways

• Dna Replication
• Cell Cycle
• S Phase
• Cell Proliferation
• Localization
• Mitosis
• Cell Growth
• G1 Phase
• Cell Division
• Pathogenesis
• Regulation Of Dna Replication
• M Phase
• Dna Replication Initiation

• Cell Cycle Arrest
• Rna Interference
• Metaphase
• Dna Repair
• Regeneration
• Fertilization
• Neurogenesis

PTMs

• Phosphorylation
• Cleavage
• Acetylation

• Ubiquitination
• Dephosphorylation
• Methylation

Research Areas

• Cell Cycle and Replication
• Cellular Markers
• Core ESC-Like Genes
• DNA Repair
• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MCM7

Boster Bio - Best Uses Of The MCM7 Marker

The most well-known biomarkers for testing are Ki-67 and CDC47. While some of these markers are more specific to individual conditions Boster Bio's MCM7 marker is generally applicable to all research. These markers have an excellent correlation with Ki-67 and CDC47. Continue reading to find out more about their applications.

Positive correlation with Ki-67

In a previous study a positive correlation between APT SI (and Ki-67 LI) was observed in patients suffering from cancers of the rectal or glioma. These studies weren't statistically significant as they were conducted on the same samples. These results could be explained by the high percentage of tumor cells with Ki-67 expressing. Furthermore, the tudy a was calculated from a ROI that covered the entire tumor, including necrosis.

3D pCASL in comparison to IVIM, is more precise than IVIM when assessing NPC's growth status. The most effective biomarker for discerning Ki67 levels that are high and low in PCa is the BFmax. DCE-MRI therefore can provide positive correlations between Ki-67 levels and PCa. Further research into this subject is required. To this end, this study is a valuable source for clinicians.

In addition to Ki-67, IVIM provides other quantitative imaging parameters. Its BFmax and BFmin values were significantly higher than those in high-grade GNGT. The FA measures showed a positive correlation with Ki-67. Additionally, the highest FA had greater sensitiveness and specificity when it came to making a grade for GNGT that was not enhanced. Both BFmax and ADCmean were highly correlated with Ki-67.

tudyimaging has been utilized in the diagnosis of breast cancer however, there are only a few studies that have examined its utility. Further research is needed to determine if tudy a and Ki67 LI are connected. It is still not clear whether tudy a and Ki-67 Li should be used in combination for different diagnostics, despite evidence. This test is a good indication for the time being. So what is the positive correlation between Ki-67 and Ki-67?

Utility in prostatic Neoplasia

A novel marker for prostate cancer has been discovered. The MCM7 gene, which is highly expressed in prostate tissue and has a high probability of survival. Its presence is also linked to aggressive therapy, such as radiotherapy and radical prostatectomy. More research is needed to determine its effectiveness in identifying prostatic cancer. These are just a few of its benefits.

The MCM7 gene belongs to the protein known as pre-replication, which is involved in DNA replication. The gene has been studied for its utility in determining the progression of prostate neoplasia. Its levels are consistent with Ki67 levels and have shown better distinction between adenocarcinoma and PIN. This gene is an excellent candidate for diagnosing prostatic cancer, but more research is required to prove its utility.

In this study, MCM7 expression was increased in 80% of prostate cancer cells as compared to normal tissues. However, there was no PSA expression in the sections studied. Further functional studies are required to determine whether MCM7 is a reliable marker of prostatic neoplasia. In the meantime, these findings are promising and warrant further investigation.

In addition to its prostatic cancer utility In addition to its prostatic cancer-related benefits, the MCM7 gene also plays an important role in the diagnosis of cancer. While many tumors could have high levels of this gene, certain cells may also display low levels. Additionally, it could be used as a predictive marker for the creation of effective treatment strategies. The identification of new tumor markers further enhances the efficacy of MCM7 for the treatment of prostatic neoplasia.

Pi > Ki67

One study utilized the PI > Ki-67 metric for predicting the survival of patients with breast cancer. The authors divided their subjects into two groups based on Ki-67 positivity: 25 percent of patients with a high Pa and 25 percent of patients with a low PI. According to the authors they found that high Pa was associated more with survival than low PI. The study was hampered by the small sample size, subjective scoring of positive nuclei and the limitations of the study.

The Pa was measured by using antibodies against Ki-67 which is a nuclear antigen. The Ki-67 antigen is found on the surface most human cells. These antibodies can be used to retrospectively examine cancerous neoplasia as well as estimate the proliferative fraction. Ki-67 also was used to examine immune-expression in colorectal cancers , and the relationship between histological stage and grade.

TuBB-9, a brand new antibody, detected the pKi67 gene in a proliferating cells. TuBB-9 detected pKi67-related chromatin from rRNA gene clusters. Ki-67 is expressed in all chromosomes but is not present in the centromere, indicating that the centromeric gap is controlled by a specific chromatin. Ki-67 has a role in early rRNA synthesis.

The ratio PI > Ki-67 does not provide an accurate indicator of the growth rate of tumors in colorectal cancer. A low Ki-67 level is associated with better survival rates, while high Ki-67 is linked to poor clinical outcomes. Although high Ki-67 PI could be a poor biomarker of prognosis but it shouldn't be used to make treatment decisions however, it is an important one. Ki-67's immunoreactivity in colorectal cancer is often a biomarker for treatment for cancer. Blocking Ki-67 can arrest the proliferation of cancerous cells.

t poor prognosis for PSCC is due to high Pa. Positive Ki-67 can be a sign of HPV infection or lymph node metastasis. Tissue microarrays have been performed on 148 formalin fixed, paraffin-embedded PSCC specimens. The related HPV DNA was identified using the INNOLiPA assay. The results revealed that Stage C is associated with high Pa and Stage Ia and IIa tumours are associated with low PI.

PI > CDC47

The antibody PI > CDC47 in Boster is produced in high-affinity monoclonal rabbit polyclonal antibody. The antibodies have been extensively studied and validated over the last 25 years. They are also proven on Western Blotting, Immunohistochemistry, and ELISA. Boster is the most popular rabbit polyclonal antibody available on the market.